Lidocaine Patch for Adjunct Analgesia for Postoperative Cesarean Birth Patients
Phase: PHASE4
Conditions: Pain, Postoperative
Sponsor: Oregon Health and Science University

 
 
 
Official Title: Lidocaine Patch for Adjunct Analgesia for Postoperative Cesarean Birth Patients  
 
 
 
 
 
Principal Investigator: Catherine Leclair, MD 
 
 
 
Professor, Department of Obstetrics and Gynecology, Oregon Health & Science University  
 
 
 
 
 
NCT No. 03500211  
 
 
 
 
Protocol Version Date: 28 September 2018 
 
 

IRB proposal 
 
Protocol Title: Lidocaine patch for adjunct analgesia for postoperative cesarean birth 
patients 
 
PI: Catherine Leclair, MD, Obstetrics and Gynecology  
 
IRB # 16657 
 
1) 
Objectives 
Purpose: Determine if lidocaine patch is effective for adjunctive analgesia in 
postoperative pain for cesarean birth patients. 
 
Hypothesis: Lidocaine patches are an effective adjunct for postoperative pain for patients 
in the acute postoperative state from cesarean birth and result in decreased pain scores on 
a visual analogue score and decreased narcotic use.  
 
Objective: Determine if a lidocaine patch is superior to placebo in achieving analgesia in 
acute postoperative cesarean birth patients.  
 
Primary endpoint  
1. To determine if lidocaine patch is superior to placebo as an adjunctive 
therapy for acute postoperative pain. This will be determined by 
comparing patient scores on an 11 point (0-10) visual analogue scale. 
 
Secondary endpoints 
2. To determine if narcotic use changes when patients use lidocaine 
patches by counting amount and frequency of narcotic use over 
admission. 
3. Use a 2 question survey asking patient and provider about satisfaction 
with patch in managing postoperative pain 
4. To determine if number of previous cesarean births contribute to the 
experience of postoperative pain. 
5. To determine if length of time in the operating room is associated with 
increased postoperative pain (incision to dressing). 
6. To evaluate if length of stay is associated with lidocaine patch use. 
2) 
Background 
Using non-opiate adjunctive medications to enhance or improve post-operative pain is a 
recent area of focus in anesthesia. Topical lidocaine patches have been FDA approved for 
postherpectic neuralgia and are thought to provide effective analgesia to nerve receptors in 
the skin. The ability of the lidocaine patch to directly mediate cutaneous nerves makes it a 
desirable choice to treat acute post-operative incisional pain. As such these patches have 
been used in the acute postoperative setting for treating incisional pain after laparoscopic 

and open abdominal procedures (Gilhooly et al 2011, Saber et al 20091). The efficacy of a 
lidocaine patch in treating acute postoperative pain as an adjunct to opioids is not well 
studied and specifically has not been studied in obstetric surgery. Despite the lack of 
evidence there is a theoretical benefit that these patches may be useful for pain control and 
use should be considered to decrease use of systemic narcotics.  
 
Patients who undergo cesarean birth have two types of pain: visceral and somatic. Somatic 
pain arises from direct tissue trauma from the surgical incision, whereas visceral pain is 
thought to bei secondary to the inflammatory proteins released in response of healing and is 
associated with visceral organs.  After a cesarean birth a patient perceives pain through 
distinct neurological pathways. Somatic pain is transmitted via the anterior division of 
spinal segmental nerves, whereas visceral uterine nociceptive stimuli return to the central 
nervous system via afferent nerve fibers that ascend through the inferior hypogastric plexus 
and enter the spinal cord via the T10-L1 spinal nerves (Lavand’homme 2006). It is thought 
that both of these pathways need to be treated for appropriate pain control in a post 
cesarean birth patient. Appropriate pain control is crucial. Data shows that optimal 
postoperative pain control is important for long term health as there are some studies that 
have shown that poor pain control in the acute setting post cesarean is a risk factor for 
pelvic pain or chronic pain (Lavand’homme 2006) (Lavoie and Toledo 2014) (Andreae and 
Andreae 2012). Traditionally, narcotic medications have been used for this and though 
effective have a concerning side effect profile particularly for postpartum patients. This has 
led clinical advocacy groups to call for strategies to minimize use.  
 
Narcotic pain medications are effective in treating both somatic and visceral pain in the 
acute setting but have a  side effect profile of sedation, dizziness, passage through breast 
milk and constipation (Reviewed in Verstraete and Van de Velde 2012). This is particularly 
challenging in the postpartum patient for several reasons: Post-delivery, breastfeeding is 
recommended every 2-3 hours, thus a medication that is sedating can lead to difficulty 
breastfeeding and could actually be dangerous if a mother falls asleep with a baby in her 
arms. Additionally, in the acute postoperative setting both pelvic surgery and the acute 
postpartum state contribute to DVT risk and early ambulation is highly encouraged. Opioid 
medication that leads to dizziness and sedation makes early ambulation and thus DVT 
prophylaxis more difficult for patients. Moreover, although there is data that the amount of 
opioids that get into breastmilk is low, there have been case reports of infant deaths 
secondary to narcotic absorption and hypermetabolism of routine post op narcotic pain 
medications. Most postpartum mothers wish to limit the amount of narcotic that there baby 
is exposed to. In addition to specific risks associated with infant care and breastfeeding, 
there are other specific issues with narcotic use in the postpartum setting.  In the acute 
postpartum period both high progesterone levels and breastfeeding can contribute to 
constipation which can be severe; all narcotic medications cause additional constipation in 
these patients already pre-disposed to this problem.  Because of all of the aforementioned 
reasons, there are many groups like the Center for Disease Control and the American Pain 
Society that advocate for minimizing narcotic use particularly in obstetric populations. 
Thus, post-operative pain from cesarean birth deserves a multimodal analgesia to optimize 
pain management and minimize narcotics. The use of adjuncts to narcotic pain medications 
would “minimize (narcotic)-related side effects to the mother and her infant therefore 

allowing for early return to baseline function and preventing a prolonged hospital length of 
stay” (Lavoie and Toledo 2014).  
 
A recent Cochrane review concluded that “Local analgesia infiltration and abdominal nerve 
blocks as adjuncts to regional analgesia and general anesthesia are of benefit in caesarean 
birth by reducing opioid consumption” (Bamigboye A and Hofmeyr G 2009). In particular, 
the local analgesic effect of a lidocaine patch is particularly an attractive feature for breast 
feeding patients who are interested in minimizing narcotic use.  In one report, a patient who 
was unable to use any narcotic pain medications used 5% lidocaine patches as primary 
analgesia post cesarean birth with good success (Gilhooly et al 2011) indicating that a 
lidocaine patch may specifically have a role in post cesarean multimodal analgesia. 
Additionally, a lidocaine patch is currently being used in approximately 50% of patients 
who undergo cesarean birth at OHSU (unpublished) and is part of the standard post-
operative order set but has never been studied in this patient population. Therefore, a study 
examining whether the lidocaine (Lidoderm®) patch is effective as a component of 
multimodal analgesia post cesarean birth is justified.  
 
Lidocaine patches are likely safe to use in the post cesarean patient with little systemic 
absorption and negligible amounts being excreted into breast milk. No studies currently 
exist evaluating this population.  However, pharmokinetics (Micromedex, Gammaitoni 
20032) show that systemic absorption is low at peak half-life and well below the level of 
concern for cardiac effects. Serum levels are directly related to the duration of use and the 
surface area of application. In one study where THREE patches (2100mg) were placed 
simultaneously, the area of distribution was 420cm2. Blood levels during patch use and 12 
hours following patch removal showed only 64mg ± 32mg was absorbed and serum levels 
were 0.13 ± 0.06 micrograms/mL.  The mean serum peak of 0.13 micrograms/mL is 
approximately 1/10 the amount needed to treat a cardiac arrhythmia.  Approximately 5% of 
the total amount of lidocaine is absorbed from the patch with the majority of medication 
remaining in the used patch. Additionally, repeated dosing over three days did not show 

increased serum levels. In our proposed study, we intend to use ONE patch over a 
distribution of 14x2 cm2 on the lower abdomen, much below the stated level.  
 
 
Figure 1  
Mean lidocaine blood concentrations after three consecutive daily applications of three 
LIDODERM patches simultaneously for 12 hours per day in healthy volunteers (n = 15). 
 
The following study tests the hypothesis that topical lidocaine patches (Lidoderm® patch) 
are an effective adjunct to traditional medications after cesarean birth by decreasing pain 
scores, decreasing opiate use and improving patient satisfaction. Specifically, we are 
proposing a randomized control trial of patients undergoing scheduled or non-urgent 
cesarean birth to 5% lidocaine patch (Lidoderm® patch) versus placebo-patch in addition 
to standard post op pain regimens for patients undergoing scheduled or non-urgent cesarean 
births.  
 
3) 
Study Design – Randomized control trial with a treatment group receiving a topical 
lidocaine patch and a control group receiving a placebo patch  
 
4) 
Study Population 
a. Number of Subjects: 50 total, 25 for each group, will be randomized in this study. 
Additional participants (up to 75 total) will be consented to participate but may not be 

randomized due to changes in their eligibility status between consenting and 
randomization. Accurate numbers will be reported annually with continuing review. 
 
b. Inclusion and Exclusion Criteria: 
Patients will be screened at the time of consent for cesarean birth. Patients will be 
given a written form explaining the study in addition to the verbal description. The 
patient must be able to give verbal and written consent.  
 
Inclusion criteria 
1. Pregnant patients > 18yo who require a scheduled or non-urgent 
cesarean birth 
2. Patient able to receive neuraxial analgesia 
3. Verbal and written consent were able to be obtained for both cesarean 
birth and study 
 
Exclusion criteria 
1. Patients requiring emergent cesarean birth 
2. Women allergic to lidocaine 
3. Patients who have already received an epidural during this admission 
4. Women using chronic oral neuromodulators such as oral gabapentin, 
oral pre-gabalin, oral trycyclic antidepressants, oral serotonin-norepi 
reuptake inhibitor, or other oral neurmodulators.  
5. Patients with cardiac disease 
6. Patients using anti-arrhythmic agents 
7. Patients with allergy to adhesive 
8. Patients requiring general anesthesia for cesarean birth 
9. Patients with fibromyalgia or chronic pain syndromes such as 
rheumatoid arthritis, osteoarthritis, or lupus. 
10. Daily narcotic or opiate use for greater than the 2 months prior to 
enrollment in the study.  
 
 
 
 
c. Vulnerable Populations: Women less than18yo or unable to give consent will be 
excluded from the study. This study involves consenting women while they are 
pregnant but involves women who are postpartum.  
 
d. Setting: This study will occur in the labor and delivery unit at OHSU. Recruitment 
and consent will be done by study staff, residents and faculty in the OHSU clinics or 
on labor and delivery. Data analysis will be done by study staff in the OB-GYN and 
Anesthesia department with support from the Women’s Health Research Unit.  

e. Recruitment and Consent  
Eligible subjects will be identified with pre-review of the OHSU L&D schedule as 
well as at time of presentation to Labor and Delivery. Whenever possible the subjects 
will be approached by study staff regarding the study and consented in the clinic prior 
to their scheduled procedure. If the patient is not enrolled prior to their procedure, 
then a verbal discussion will occur on the labor floor. Written information will be 
provided to patients through the IRB approved consent form. The consenting study 
staff or physician will enroll and consent interested patients. Eligible non-English 
speaking patients may participate in this study. An interpreter will be utilized in the 
consent process for non-English speaking patients. No compensation will be given for 
participation. 
 
This proposal involves minimal risk and employs a patch that is already FDA 
approved for pain management.  It has not been approved specifically for post-
operative pain management and cesarean birth. Information will be provided by both 
the trained consenting physician and information provided in the consent document. 
As described above, patients unable to consent will be excluded from the study.  
 
f. Blinding: In order to minimize potential for bias with regard to the subjective study 
outcome (perception of pain on VAS), all efforts will be made to keep the participants 
blinded at the time of patch placement. In addition, all efforts will be made to keep 
the study staff conducting the follow-up questions, symptoms and clinical findings, 
unaware of outcome measures until at the least the end of the first scheduled follow 
up. The clinical staff placing the study patch will be trained in the procedures of 
placement and will be prepared to shield the participant from view of the patch type. 
This may be accompanied by asking the participant to hold a physical barrier (i.e. 
magazine) in front of her closed eyes.   
 
g. Investigational New Drug (IND): The study team determined that the use of 
lidocaine patch should be exempt from an IND based on the criteria below. Lidocaine 
patch is an FDA-approved drug for an unapproved use, but should be exempt because 
the following criteria are true about our investigation: 
• The investigation is not intended to be reported to the FDA in support of a 
new indication for use nor intended to be used to support any other significant 
change in the labeling for this drug. While it is FDA-approved for post 
herpetic neuralgia, it is commonly used for postoperative pain management as 
supported in these studies (Kwon et al 20123, White et al 20104, Gan et al 
20145).  
• The investigation is not intended to support a significant change in the 
advertising for the product 
• The investigation does not involve a route of administration or dosage level or 
use in a patient population or other factor that significantly increases the risk 
associated with the product. 
 

h. Cost: The study drug and supplies for the placebo patch will be billed to a study 
account and there will be no additional costs to the patient or the patient’s insurance 
for participating in the study.  
 
Procedures  
1. The research team will assemble packets prior to the start of the study. The packet will 
include 4 copies of the 11-point visual analog scale (see attached). Each packet will be 
numbered 1-50. The packets will be randomized to either the lidocaine patch or the 
placebo patch arm using www.randomization.com. The envelope will also include a 
role of Elastikon© tape and a piece of white Tegaderm© in the dimensions of the patch 
used to place over the study medication.  
2. Patient presents to L&D for either a scheduled cesarean delivery or a non-urgent 
cesarean birth. 
3. While in the preoperative state, the patient will be approached by a consenting resident 
or study staff as to their interest in the study. Risks, including contact dermatitis in the 
area of patch placement, and benefits, including improved pain control and potentially 
less narcotic use, will be discussed with the patient. Enrollment in the study and 
consents will be signed at that time. Information will be collected about patients’ use of 
drugs/opiates. 
4. When placing admission orders for all study patients, a lidocaine study order set will be 
placed on their MAR as a PRN to be started 12 hours post operatively. The study drug 
and placebo packets will be stored in the Pixis to be retrieved by the patients nurse and 
handed to the resident at the time of administration. Medication use will follow the 
manufacturer’s instructions. The patch will be placed q 24 hours, with patches removed 
12 hours after placement. Lidocaine patch is used no greater than 12 hours within a 24-
hour period.  
5. The consenting physician will then draw a pre-randomized envelope from a binder in 
the staff work area on labor and delivery and place it on the patients L&D clip board. 
The envelope will assign a consented patient to either the treatment arm or the control 
arm. The treatment arm will be blinded from the patient.  
6. Patient undergoes cesarean with a standardized anesthesia regimen including: 15 mcg 
intrathecal (IT) fentanyl, 150 mcg IT morphine, 12.75 mg IT bupivacaine. 30mg of IV 
ketorolac will be given at the completion of the procedure unless contraindicated. A 
1,000mg acetaminophen rectal suppository will be placed after the sterile drapes are 
removed and prior to transfer to the PACU. Patients will not routinely be given IV 
NSAIDs (Toradol®) at the end of the case.  
7. 12 hours will elapse before the first study patch is placed. This is to allow the 
neuroaxial anesthesia to wear off so that full effect of the patch medication can be 
appreciated. At 12 hours postoperative, the patient has secured placement on the 
postpartum floor, 13C, Mother Baby Unit (MBU). 
8. 12 hours post cesarean an OHSU OBGYN resident will go to the patient’s room after 
obtaining the study patch from the pixis (lidocaine is on the MAR for PRN 
postoperative medication use) or placebo patch from the study envelope.  The patch 
will be cut in half, down the long axis of the patch. Each half will be placed, 2cm above 

and 2cm below the patient’s incision (as seen below). Since the Lidocaine patch must 
be placed over intact skin, it will not be placed over the incision directly.  
 
Umbilicus middle arrow, blue box=patch placed 2 cm above and below the incision, black line=Pfannestiel incision 
line 
 
9. 12 hours post operatively, study staff, will also obtain pain VAS (visual analogue scale) 
at the time of patch placement. Steps include: 
a. Ask patient to grade their current pain on a printed visual analog scale (see 
attached copy of VAS scale) before the patch is applied 
b. Staff place the patch (according to procedures in step 8)  
c. Staff will then place Elastikon© tape over the patients patch (in study packet), 
covering the patch completely. 
d. 24-hour post operatively the patch with accompanying tape will be removed by 
the staff.  
e. The patient will fill out a second VAS rating their current pain  
f. 36 hours post operatively staff will place second patch (same as the patients 
first) in the area surrounding their incision. Repeating steps a-f.  
48-hour post operatively the patch and surrounding tape will be removed by the 
staff and the patient will fill out visual analog scale rating their current pain. 
g. Prior to discharge the total IV and PO narcotic medication that the patient took 
during their hospitalization will be recorded.  
 
10. Post operative day 5, a secure email message through RedCap or phone call to patient 
to determine how many oxycodone they have used since discharge. The exact message 
will be:  
“ Hi, this is the study staff from OHSU Women’s Health Research Unit. We hope you 
are feeling well after your surgery. Please respond to this message with how often you 
are taking your narcotic prescription (ie: Oxycodone, Norco, Percocet, Vicoden) and 
how many pills you have left in your bottle. Thank you and congratulations! – OHSU 
Women’s Health Research Unit”  
 
Time Postop 
12 hours 
24hours 
36 hours 
48 hours 
5 days Post- 
partum 

Patch 
placed 
removed 
placed 
removed 
 
 
Pain 
questionnaire 
VAS 
x 
x 
x 
x 
 
Chart review 
 
x 
 
x 
 
Epic MyChart 
Message 
 
 
 
 
x 
 
 
5) 
Data and Specimens 
a) Sharing of Results with Subjects 
Research related results will not be shared with the subjects. 
 
b) Data and Specimen Banking 
Data from chart analysis and review will be stored in RedCap. The research subjects will 
be given a unique study ID number, and all materials will be labeled with that coded 
identifier. All study documents will be stored in locked offices at either the Center for 
Women's Health or the Women's Health Research Unit.  Data will be put into the 
Woman’s Health Research Unit repository for future analysis.  Those in the obstetrics 
and gynecology and anesthesia department who have gone through training on human 
subject research may access the electronic data in the future for additional analysis.  
 
6) 
Data Analysis 
The main comparison is a 11-point (0-10) Visual Analog Scale at 24-hour post-op between 
two group with the hypothesis that lidocaine patch will decrease the pain at 24hr 
significantly (more than 15mm). Sample size of 25 per each group achieve 82.3% power to 
detect a difference of 15mm between two group assuming controls will have mean (SD) of 
36mm (18mm)6 and lidocaine group will have mean (SD) of 21mm (18mm) with a 
significance level of 0.05 using two-sided two sample t-test. 
 
7) 
Privacy, Confidentiality and Data Security 
Upon enrollment subjects will be assigned a unique study ID number that will be used 
instead of their name, medical record number or other personally identifying information. 
Electronic files for data analysis will be labeled with that coded identifier. Codes will not 
contain any part of the 18 HIPAA identifiers. The key associating the codes and the 
subjects personally identifying information will be restricted to the PI and the study staff 
and will be password protected. The key will be kept secure on a restricted OHSU network 
drive in a limited access folder. All hard copied of study documents will be stored in locked 
offices at either the Center for Women's Health or the Women's Health Research Unit. 
 
The investigators and study staff will report any AEs or UPs to the monitoring entity within 
24 hours of their occurrence via paging, e-mail, or phone call. The details of the events will 
be appropriately documented and filed in the subject's chart. 
 
If the event is deemed a UP by the monitoring entity, she will prepare a UP for submission to the 
IRB. The report will be submitted as per the OHSU UP policy: within 7 calendar days of the 

monitoring entity's knowledge for deaths and life-threatening events considered to be UPs or within 
15 calendar days of the monitoring entity's knowledge for all other events that are considered UPs. 
 
The PI or co-investigators will review of study charts upon completion of 25 subjects 
(halfway) and again at the study’s conclusion. Anytime that an AE, SAE, UP, medication 
toxicity, or protocol deviation is reported by an investigator or study staff, the monitoring 
entity will review and assess study chart and patient information, and proceed as per OHSU 
reporting policy. All adverse events will be assessed and reportable UPs will be submitted 
to the IRB, if judged related to the study protocol. 
 
8) 
Risks and Benefits  
a) Risks to Subjects 
Patients who are randomized to the placebo arm may have higher pain scores and 
experience more postoperative pain.  
 
The medication in the lidocaine patches is absorbed locally but there is a theoretical risk 
that this could be systemically absorbed. The current use and lack of reported side effects 
suggests that this is a theoretical risk only.  
 
b) Potential Benefits to Subjects 
There is no direct benefit for participating in this study other than improved pain control. 
 
 
 
 
 
 
 
 
References: 
1. Saber AA et al, Early experience with lidocaine patch for postoperative pain control after 
laparoscopic ventral hernia repair, Int J Surg 2009; 7(1): 36-8. 
2. Gammaitoni et al, Safety and tolerability of the lidocaine patch 5%, a targeted peripheral 
analgesic: a reviw of the literature; J Clinic Pharmacolo 2003, 43(2): 111-117. 
3. Kwon et al, Treatment for post operative wound pain in gynecologic laparoscopic 
surgery: topical lidocaine patches. J Laparoendosc Adv Surg Tech A. 2012 
Sep;22(7):668-73 
4. White PF, Kehlet H. Improving postoperative pain management: what are the unresolved 
issues? Anesthesiology 2010;112:220-5 
5. Gan TJ, Habib AS, Miller TE, et al. Incidence, patient satisfaction, and perceptions of 
post-surgical pain: results from a US national survey. Curr Med Res Opin 2014;30:149-
60 
6. M Khooshideh et al.. Pulsed Electromagnetic Fields for Postsurgical Pain Management in 
Women Undergoing Cesarean Section: A Randomized Double-blind, Placebo-controlled 
Trial.  Clinical Journal of Pain. Feb 2017; 33(2):142-147